| 研究課題/領域番号 |
19K17925
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分54030:感染症内科学関連
|
|---|
| 研究機関 | 大阪大学 (2021-2022)
神戸大学 (2019) |
|---|
研究代表者 |
オフィンニ ユディル 大阪大学, 免疫学フロンティア研究センター, 特任研究員(常勤) (30837901)
|
|---|
| 研究期間 (年度) |
2021-03-01 – 2023-03-31
|
| 研究課題ステータス |
中途終了 (2022年度)
|
| 配分額 *注記 |
4,290千円 (直接経費: 3,300千円、間接経費: 990千円)
2020年度: 1,820千円 (直接経費: 1,400千円、間接経費: 420千円)
2019年度: 2,470千円 (直接経費: 1,900千円、間接経費: 570千円)
|
|---|
| キーワード | HIV-1 / iPSC / CRISPR/Cas9 / T cell / Feeder-free / Lentivirus |
|---|
| 研究開始時の研究の概要 |
HIV-1 infection is incurable. To cure HIV-1 infection, direct disruption of viral gene is necessary. We previously have developed anti-HIV gene editing using CRISPR/Cas9. To proceed into clinical application, usage of stem cells is the most promising. We plan to use induced pluripotent stem cells (iPSC) to generate large supply of T cells. Thus, our study plan is to efficiently develop iPSC containing anti-HIV-1 CRISPR/Cas9, and differentiate iPSC to generate HIV-1 resistant T cells. Successful generation may lead to a clinically applicable, complete cure for HIV-1.
|
| 研究実績の概要 |
Step 1 of the study has been published in Viruses in 2020 and selected as a cover story of the journal's #11 issue. In Step 2, I have successfully transduced Cas9-gRNA into human mobilized hematopoietic stem cells (HSC) using a lentivector with Cocal virus pseudotyped-envelope. But, Step 3 did not go well as I moved to the US (HIV lab in Harvard), Osaka (Immunology), and now Kobe (Clinical Virology). The labs were not an iPSC lab. iPSC differentiation needed strict protocol and culture environment, and I did not succeed in differentiating the transduced iPSC. I am still hoping to establish a position in an iPSC lab to continue the project.
I prematurely ended the KAKENHI project as I was adopted as a Program-Specific Assistant Professor in Kobe and cannot have any extra research effort.
|
